Intervention Review

Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease

  1. Robert Caslake2,
  2. Angus Macleod3,
  3. Natalie Ives4,
  4. Rebecca Stowe4,
  5. Carl Counsell1,*

Editorial Group: Cochrane Movement Disorders Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 19 FEB 2009

DOI: 10.1002/14651858.CD006661.pub2

How to Cite

Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD006661. DOI: 10.1002/14651858.CD006661.pub2.

Author Information

  1. 1

    University of Aberdeen, Division of Applied Health Sciences, Aberdeen, UK

  2. 2

    University of Aberdeen, Medecine & Therapeutics, Aberdeen, UK

  3. 3

    University of Aberdeen, Medicine and Therapeutics, Aberdeen, UK

  4. 4

    Robert Aitken Institute, University of Birmingham, Birmingham Clinical Trials Unit, School of Cancer Sciences, Birmingham, UK

*Carl Counsell, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. carl.counsell@abdn.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 7 OCT 2009

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    T. Keränen, T. Mattila, T. Luukkaala, H. Kuusisto, Retention rate of selegiline in early Parkinson’s disease: a retrospective survey, International Journal of Clinical Practice, 2012, 66, 10